FGF-23, Vascular Calcification, and Cardiovascular Diseases in Chronic Hemodialysis Patients

Overview

Journal Int Urol Nephrol

Publisher Springer

Specialty Nephrology

Date 2013 Apr 4

PMID 23549862

Citations 10

Authors

Diana Moldovan

Ioan Moldovan

Crina Rusu

Ina Kacso

Ioan Mihai Patiu

Mirela Gherman-Caprioara

Affiliations

Soon will be listed here.

Abstract

Introduction: Chronic hemodialysis (HD) patients have bad prognosis and cardiovascular diseases (CVD) represent their main threatening complication. Fibroblast growth factor (FGF-23) has been associated with all kinds of evil consequences, including cardiovascular morbidity, but some studies demonstrated the contrary. Therefore, it is important to know whether FGF-23 is associated with cardiovascular risk or protection. The purpose of this study was to assess the links between FGF-23 and intimal vascular calcification (VC) and with the presence of CVD in chronic HD patients.

Patients And Methods: This study was carried out on a cohort of randomly selected 88 prevalent HD patients. We recorded demographical, clinical, and biochemical data, including FGF-23. VC was evaluated on carotid ultrasound. CVD were registered.

Results: The mean age was 59.68 ± 14.49 years, HD vintage was 59.61 ± 52.39 months, and 20 patients were diabetic (22.72 %). VC was present in 54 patients (61.4 %) and 25 patients (28.4 %) had CVD. FGF-23 correlated positively with HD vintage (r = 0.37; p < 0.001) and iPTH (r = 0.21; p = 0.048). FGF-23 did not correlate with VC score. Patients with CVD were older (p = 0.006), had lower FGF-23 (p = 0.008), higher VC score (p = 0.009), lower Hb (p = 0.008), albumin (p = 0.003), and creatinine (p = 0.03). Low FGF-23 was identified as a risk factor for CVD.

Conclusion: We report on a novel association between low FGF23 and CVD in chronic HD patients and a lack of correlation of FGF-23 with VC. FGF-23 could play a role in cardiovascular protection that remains to be confirmed in larger studies.

Citing Articles

FGF-23 and sclerostin in serum and bone of CKD patients.

Lima F, Monier-Faugere M, Mawad H, David V, Malluche H Clin Nephrol. 2023; 99(5):209-218.

PMID: 36970967 PMC: 10286735. DOI: 10.5414/CN111111.

Kernelized -Local Hyperplane Distance Nearest-Neighbor Model for Predicting Cerebrovascular Disease in Patients With End-Stage Renal Disease.

Liu X, Zhang X, Zhang Y, Ding Y, Shan W, Huang Y Front Neurosci. 2021; 15:773208.

PMID: 34759797 PMC: 8573245. DOI: 10.3389/fnins.2021.773208.

A Self-Representation-Based Fuzzy SVM Model for Predicting Vascular Calcification of Hemodialysis Patients.

Liu X, Zhang X, Guo X, Ding Y, Shan W, Wang L Comput Math Methods Med. 2021; 2021:2464821.

PMID: 34367315 PMC: 8337133. DOI: 10.1155/2021/2464821.

Iron, coronary artery calcification, and mortality in patients undergoing hemodialysis.

Mizuiri S, Nishizawa Y, Doi T, Yamashita K, Shigemoto K, Usui K Ren Fail. 2021; 43(1):371-380.

PMID: 33596750 PMC: 7894440. DOI: 10.1080/0886022X.2021.1880937.

Fibroblast growth factor 23 (FGF23) level is associated with ultrafiltration rate in patients on hemodialysis.

Nishizawa Y, Hosoda Y, Horimoto A, Omae K, Ito K, Higuchi C Heart Vessels. 2020; 36(3):414-423.

PMID: 33000285 PMC: 7872991. DOI: 10.1007/s00380-020-01704-y.

References

Isakova T, Xie H, Yang W, Xie D, Anderson A, Scialla J . Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305(23):2432-9. PMC: 3124770. DOI: 10.1001/jama.2011.826. View

Fliser D, Kollerits B, Neyer U, Ankerst D, Lhotta K, Lingenhel A . Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol. 2007; 18(9):2600-8. DOI: 10.1681/ASN.2006080936. View

Mirza M, Hansen T, Johansson L, Ahlstrom H, Larsson A, Lind L . Relationship between circulating FGF23 and total body atherosclerosis in the community. Nephrol Dial Transplant. 2009; 24(10):3125-31. DOI: 10.1093/ndt/gfp205. View

Seiler S, Cremers B, Rebling N, Hornof F, Jeken J, Kersting S . The phosphatonin fibroblast growth factor 23 links calcium-phosphate metabolism with left-ventricular dysfunction and atrial fibrillation. Eur Heart J. 2011; 32(21):2688-96. DOI: 10.1093/eurheartj/ehr215. View

Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T . Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest. 2004; 113(4):561-8. PMC: 338262. DOI: 10.1172/JCI19081. View

Kirkpantur A, Balci M, Gurbuz O, Afsar B, Canbakan B, Akdemir R . Serum fibroblast growth factor-23 (FGF-23) levels are independently associated with left ventricular mass and myocardial performance index in maintenance haemodialysis patients. Nephrol Dial Transplant. 2010; 26(4):1346-54. DOI: 10.1093/ndt/gfq539. View

Razzaque M . The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol. 2009; 5(11):611-9. PMC: 3107967. DOI: 10.1038/nrendo.2009.196. View

Shalhoub V, Shatzen E, Ward S, Davis J, Stevens J, Bi V . FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest. 2012; 122(7):2543-53. PMC: 3386816. DOI: 10.1172/JCI61405. View

Taylor E, Rimm E, Stampfer M, Curhan G . Plasma fibroblast growth factor 23, parathyroid hormone, phosphorus, and risk of coronary heart disease. Am Heart J. 2011; 161(5):956-62. PMC: 3095912. DOI: 10.1016/j.ahj.2011.02.012. View

10.

Bernheim J, Benchetrit S . The potential roles of FGF23 and Klotho in the prognosis of renal and cardiovascular diseases. Nephrol Dial Transplant. 2011; 26(8):2433-8. DOI: 10.1093/ndt/gfr208. View

11.

Coen G, De Paolis P, Ballanti P, Pierantozzi A, Pisano S, Sardella D . Peripheral artery calcifications evaluated by histology correlate to those detected by CT: relationships with fetuin-A and FGF-23. J Nephrol. 2010; 24(3):313-21. DOI: 10.5301/JN.2010.5818. View

12.

Inaba M, Okuno S, Imanishi Y, Yamada S, Shioi A, Yamakawa T . Role of fibroblast growth factor-23 in peripheral vascular calcification in non-diabetic and diabetic hemodialysis patients. Osteoporos Int. 2006; 17(10):1506-13. DOI: 10.1007/s00198-006-0154-6. View

13.

Hsu H, Wu M . Fibroblast growth factor 23: a possible cause of left ventricular hypertrophy in hemodialysis patients. Am J Med Sci. 2009; 337(2):116-22. DOI: 10.1097/MAJ.0b013e3181815498. View

14.

Block G, Klassen P, Lazarus J, Ofsthun N, Lowrie E, Chertow G . Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004; 15(8):2208-18. DOI: 10.1097/01.ASN.0000133041.27682.A2. View

15.

Jean G, Bresson E, Terrat J, Vanel T, Hurot J, Lorriaux C . Peripheral vascular calcification in long-haemodialysis patients: associated factors and survival consequences. Nephrol Dial Transplant. 2008; 24(3):948-55. DOI: 10.1093/ndt/gfn571. View

16.

London G, Guerin A, Marchais S, Metivier F, Pannier B, Adda H . Arterial media calcification in end-stage renal disease: impact on all-cause and cardiovascular mortality. Nephrol Dial Transplant. 2003; 18(9):1731-40. DOI: 10.1093/ndt/gfg414. View

17.

Moldovan D, Moldovan I, Rusu C, Racasan S, Patiu I, Brumboiu A . Vascular calcifications and renal osteodystrophy in chronic hemodialysis patients: what is the relationship between them?. Int Urol Nephrol. 2010; 43(4):1179-86. DOI: 10.1007/s11255-010-9841-5. View

18.

Drueke T . Arterial intima and media calcification: distinct entities with different pathogenesis or all the same?. Clin J Am Soc Nephrol. 2008; 3(6):1583-4. DOI: 10.2215/CJN.03250708. View

19.

Jean G, Terrat J, Vanel T, Hurot J, Lorriaux C, Mayor B . High levels of serum fibroblast growth factor (FGF)-23 are associated with increased mortality in long haemodialysis patients. Nephrol Dial Transplant. 2009; 24(9):2792-6. DOI: 10.1093/ndt/gfp191. View

20.

Stubbs J, Liu S, Tang W, Zhou J, Wang Y, Yao X . Role of hyperphosphatemia and 1,25-dihydroxyvitamin D in vascular calcification and mortality in fibroblastic growth factor 23 null mice. J Am Soc Nephrol. 2007; 18(7):2116-24. DOI: 10.1681/ASN.2006121385. View